PMID: 23394218

Authors:

Addie M, Ballard P, Buttar D, Crafter C, Currie GS, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, Johnson PD, Kettle JG, Lane C, Lamont G, Leach AG, Luke R, Morris J, Ogilvie D, Page K, Pass M, Pearson S, Ruston L

Title:

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin -4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.

Journal:

J Med Chem. 2013 Feb 11.

Abstract:

Wide ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363 which showed increased potency, reduced hERG affinity and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical DMPK properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumour growth in a breast cancer xenograft model.